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Abstract
Background: Evidence is accumulating that chronic inflammation may have an important role in prostate cancer
(PCa). The COX-2 polymorphism rs2745557 (+202 C/T) has been extensively investigated as a potential risk factor
for PCa, but the results have thus far been inconclusive. This meta-analysis was performed to derive a more precise
estimation of the association.
Methods: A comprehensive search was conducted to identify all case-control studies of COX-2 rs2745557
polymorphism and PCa risk. We used odds ratios (ORs) to assess the strength of the association, and 95%
confidence intervals (CIs) give a sense of the precision of the estimate. Statistical analyses were performed by
Review Manage, version 5.0 and Stata 10.0.
Results: A total of 8 available studies were considered in the present meta-analysis, with 11356 patients and 11641
controls for rs2745557. When all groups were pooled, there was no evidence that rs2745557 had significant
association with PCa under co-dominant, recessive, over-dominant, and allelic models. However, our analysis
suggested that rs2745557 was associated with a lower PCa risk under dominant model in overall population (OR =
0.85, 95%CI = 0.74-0.97, P = 0.02). When stratifying for race, there was a significant association between rs2745557
polymorphism and lower PCa risk in dominant model comparison in the subgroup of Caucasians (OR = 0.86, 95%
CI = 0.75-0.99, P = 0.04), but not in co-dominant, recessive, over-dominant and allelic comparisons.
Conclusion: Based on our meta-analysis, COX-2 rs2745557 was associated with a lower PCa risk under dominant
model in Caucasians.
Background
PCa is one of the most frequently diagnosed malignan-
cies and a common cause of cancer mortality in men
in the Western hemisphere [1,2]. Identifying risk fac-
tors for PCa is critically important to develop potential
interventions and to expand our understanding of the
biology of this disease. Despite the fact that the com-
plex etiology of PCa remains obscure, various risk fac-
tors play an important role in PCa development such
as advanced age, environmental variations, culture
changes, and genetic variations. A strong association
exists between states of chronic inflammation and can-
cer, and it is believed that mediators of inflammation
may be responsible for this phenomenon [3]. Chronic
inflammation may lead to tumorigenesis by damaging
DNA through radical oxygen and nitrogen species,
enhancing cell proliferation, and stimulating angiogen-
esis [4]. Some single nucleotide polymorphisms in
specific cytokine genes have been proved to influence
the expression and/or activity of encoding proteins
probably making thereby the host predispose to certain
cancer [5-7], so rs2745557 polymorphism of COX-2
that involved in the inflammatory pathway might
impact susceptibility to PCa.
COX, also known as prostaglandin-endoperoxide
synthase (PTGS), catalyzes the rate-limiting step in the
formation of inflammatory prostaglandins. COX is an
integral membrane bifunctional enzyme, which meta-
bolizes arachidonic acids to many biologically active
eicosanoids. COX-2 gene located on chromosome
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[8]. COX-2 is an inducible enzyme that converts ara-
chidonic acid to prostaglandins, which play a role in
cell proliferation and are potent mediators of inflam-
mation. A meta-analysis suggested that aspirin use was
associated a trend of decreased PCa risk [9]. The data
suggested that COX-2 is overexpressed in PCa tissue
compared to benign tissue from the same patient in
several studies [10-14]. Some previous studies sug-
gested that COX-2 may influence carcinogenesis by
inhibiting apoptosis [15], inducing angiogenesis [16]
and by chronic activation of immune responses [17].
Several polymorphisms in the COX-2 gene have been
described, such as rs5277, rs689466, rs2206593,
rs689470, and rs2745557. rs2745557 polymorphism in
intron 1 has been brought to our attention. The func-
tional impact of rs2745557, an intronic variant, on
COX-2 activity is not yet known. Several studies were
conducted to investigate the associations of COX-2
rs2745557 with PCa susceptibility [18-24]. However,
molecular epidemiological studies have yielded contra-
dictory results concerning potential roles of rs2745557
polymorphism in PCa. Individual studies might have
been underpowered to detect the overall effects. Some
studies are limited by their sample size and subsequently
suffer from too low power to detect effects that may
exist. Given the amount of accumulated data, we
deemed it important to perform a quantitative synthesis
of the evidence. Therefore, we performed this meta-ana-
lysis study to determine whether COX-2 rs2745557 was
associated with PCa risk.
Methods
Literature search
We searched the articles using the terms “COX-2” or
“PTGS2”, “prostate”, “carcinoma” or “cancer” or
“tumor”, and “polymorphism” or “variation” in PubMed,
Cochrane Library and Embase electronic databases, and
all eligible studies were published before November 15,
2011. We evaluated all associated publications to
retrieve the most eligible literatures. The reference lists
of reviews and retrieved articles were hand searched at
the same time. We did not include abstracts or unpub-
lished reports. When overlapping data of the same
patient population were included in more than one pub-
lication, only the most recent or complete study was
used in this meta-analysis. Articles were limited to Eng-
lish language papers.
Inclusion and exclusion criteria
T h ef o l l o w i n gi n c l u s i o nc r i t e r i aw e r eu s e dt os e l e c tl i t -
eratures for the meta-analysis: (1) information on the
evaluation of COX-2 rs2745557 polymorphism and PCa
susceptibility; (2) case-control studies; and (3) sufficient
genotype data were presented to calculate the OR with
95% CI. Major reasons for exclusion of studies were: (1)
no controls; (2) reviews and duplication of the previous
publication; and (3) no usable data reported.
Data extraction
A l ld a t aw e r ee x t r a c t e di n d e p e n d e n t l yb yt w oi n v e s t i g a -
tors according to the prespecified selection criteria. Dis-
agreement was resolved by discussion. The following
data were extracted: the name of the first author, publi-
cation year, ethnicity of the population, available geno-
type, number of prostate cancer cases and controls
studied and results of studies. Different descents were
categorized as Caucasian, Asian, and African American.
For case-control studies, data were extracted separately
for each group whenever possible.
Statistical analysis
The strength of the association between COX-2
rs2745557 polymorphism and PCa risk was measured by
ORs, whereas a sense of the precision of the estimate
was given by 95% CIs. The significance of the summary
OR was determined with a Z-test. We first examined
rs2745557 genotypes using co-dominant model (homo-
geneous co-dominant model: TT vs CC, heterogeneous
co-dominant model: TC vs CC), recessive (TT vs TC +
CC), over-dominant (TC vs TT + CC) and dominant
(TT + TC vs CC) genetic models. Then, the relationship
between the allele and susceptibility to PCa was exam-
ined (allelic model). Stratified analyses were also per-
formed by ethnicities. A chi-square-based Q-statistic
test and an I
2-test test were both performed to evaluate
the between-study heterogeneity of the studies. In our
study, two models of meta-analysis were applied for
dichotomous outcomes: the fixed-effects model and the
random-effects model. The fixed-effects model assumes
that studies are sampled from populations with the
same effect size, making an adjustment to the study
weights according to the in-study variance. The ran-
dom-effects model assumes that studies are taken from
populations with varying effect sizes, calculating the
study weights both from in-study and between-study
variances, considering the extent of variation, or hetero-
geneity. A P-value ≥0.10 for the Q-test indicated lack of
heterogeneity among the studies, and so the summary
OR estimate of each study was calculated by the fixed-
effects model [25]. Otherwise, the random-effects model
(DerSimonian and Laird method) was used [26]. I
2 sta-
tistic can be used to quantify heterogeneity irrespective
of the number of studies.
The significance of the pooled OR was determined by
the Z-test and P < 0.05 was considered as statistically
significant. To explore the reasons of heterogeneity,
subgroup analyses were performed by ethnicity.
Zhang et al. BMC Immunology 2012, 13:14
http://www.biomedcentral.com/1471-2172/13/14
Page 2 of 7The one-way sensitivity analyses were performed to
assess the stability of the results, namely, a single study
in the meta-analysis was deleted each time to reflect the
influence of the individual data set to the pooled OR.
To investigate whether publication bias might affect the
validity of the estimates, funnel plot were constructed.
An asymmetric plot suggests a possible publication bias.
Funnel plot asymmetry was assessed by the method of
Egger’s linear regression test, a linear regression
approach to measure funnel plot asymmetry on the nat-
ural logarithm scale of OR. The significance of the inter-
cept was determined by the t-test suggested by Egger (P
< 0.05 was considered representative of statistically sig-
nificant publication bias). All statistical tests were per-
formed with Review Manage, version 5.0 and Stata 10.0
using two-sided P-values.
Results
Eligible studies
According to the inclusion criteria defined above, we
identified 8 independent studies in 7 eligible reports
[18-24], including 11356 cases and 11641 controls. All
the included 8 eligible reports were written in English. 8
independent studies consisted of 1 Asian, 1 African
American and 6 Caucasian populations. 2 studies
included in the subgroup analysis of Caucasians also
contained a relevant proportion of subjects was not
Caucasian [20,21]. Main characteristics for all eligible
studies were listed in Table 1.
Meta-analyses
In overall population, there was significant heterogeneity
in COX-2 rs2745557 for dominant model comparison,
heterogeneous co-dominant model, over-dominant
model and allelic model comparison, except for the
homogeneous co-dominant model and recessive model
comparisons. After subgroup analyses by ethnicity, the
heterogeneity was effectively removed under allelic
model in Caucasians. The data suggested that rs2745557
was associated with a lower PCa risk under dominant
model in overall population (OR = 0.85, 95%CI = 0.74-
0.97, P = 0.02; Figure 1). However, we did not detect
the association between rs2745557 polymorphism and
PCa risk in overall population when examining the con-
trast of TT versus CC, TC versus CC, TT versus TC +
CC, TC versus TT + CC, and T allele versus C allele
(OR = 1.04, 95% CI = 0.88-1.23, P =0.66; OR = 0.88,
95% CI = 0.74-1.04, P = 0.14; OR = 1.06, 95% CI =
0.89-1.25, P = 0.51; OR = 0.88, 95% CI = 0.75-1.04, P =
0.13; and OR = 0.92, 95% CI = 0.80-1.06, P = 0.26,
respectively). Similarly, in subgroup analyses stratified by
ethnicity, the remarkable association with lower PCa risk
was detected in dominant model comparison in Cauca-
sian population (OR = 0.86, 95%CI = 0.75-0.99, P =
0.04; Figure 2). No noteworthy associations were
observed under co-dominant, recessive, over-dominant,
and allelic models in Caucasians. The detailed data were
presented in Table 2.
Sensitivity analysis
In order to compare the difference and evaluate the sen-
sitivity of the meta-analyses, we conducted one-way sen-
sitivity analysis to evaluate the stability of the meta-
analysis. The statistical significance of the results was
not altered when any single study was omitted (data not
shown), confirming the stability of the results. Hence,
Table 1 Main characteristics of studies included in this meta-analysis
First
author
Year Country Cases Controls Ethnicity rs2745557
cases
rs2745557
controls
CC
(%)
TC
(%)
TC +
TT (%)
TT
(%)
CC
(%)
TC
(%)
TC +
TT (%)
TT
(%)
Wu et
al.
2011 China 218 436 Asian 165
(75.7)
49
(22.5)
53(24.3) 4(1.8) 320
(73.4)
107
(24.5)
116
(26.6)
9
(2.1)
Amirian
et al.
2011 USA 535 533 Caucasian 372
(69.5)
163
(30.5)
353
(66.2)
180
(33.8)
Salinas
et al.
2010 USA 335 396 Caucasian 225
(67.2)
110
(32.8)
251
(63.4)
145
(36.7)
Fradet
et al.
2009 USA 466 478 Caucasian (83%), African American 337
(72.3)
129
(27.7)
301
(63.0)
177
(37.0)
Dossus
et al.
2009 USA
Europe
7941 8527 Caucasian, African-American, Latino,
native Hawaiian, Asian
5614
(70.7)
2098
(26.4)
2327
(29.3)
229
(28.8)
5954
(69.9)
2338
(27.4)
2573
(30.2)
235
(2.8)
Cheng
et al.
2007 USA 89 89 African American 69
(77.5)
19
(21.3)
20(22.5) 1(1.1) 56
(63.0)
30
(33.7)
33(37.1) 3
(3.4)
Cheng
et al.
2007 USA 417 417 Caucasian 295
(70.7)
107
(25.7)
122
(29.3)
15
(36.0)
262
(62.8)
142
(34.1)
155
(37.2)
13
(3.1)
Shahedi
et al.
2006 Sweden 1355 765 Caucasian 945
(69.7)
376
(27.7)
410
(30.3)
34
(2.5)
545
(71.2)
205
(26.8)
220
(28.8)
15
(2.0)
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this meta-analysis are relatively stable and credible.
Publication bias
Begg’s funnel plot and Egger’s test were performed to
assess the publication bias. The shape of funnel plots
did not reveal any evidence of obvious asymmetry in all
comparison models, and the Egger’s test was used to
provide statistical evidence of funnel plot symmetry.
The results did not show any evidence of publication
bias. The detailed data were present in Table 2.
Discussion
We consider the COX-2 gene highly interesting in the
search for susceptibility genes for PCa. Previous study
results suggested that single nucleotide polymorphisms
(SNPs) are the most common sources of human genetic
variation, and they may contribute to an individual’s
susceptibility to cancer [27]. In the recent years, interest
in the genetic susceptibility to cancers has led to a
growing attention to the study of polymorphisms of
genes involved in tumourigenesis. Since the identifica-
tion of COX-2 rs2745557 polymorphism, growing num-
ber of studies suggested that COX-2 rs2745557
polymorphism plays an important role in the develop-
ment of PCa. Epidemiological studies of the rs2745557
polymorphism in COX-2, if large and unbiased, can pro-
vide insight into the in vivo relationship between the
gene and PCa risk. However, these studies have
appeared in the literature either supporting or negating
the significant association. Some reviewed studies are
limited by their sample size and subsequently suffer
from too low power to detect effects that may exist. But
the pool ORs generated from much larger population
can increase the statistical power. Combining data from
many studies has the advantage of reducing random
error [28].
In order to provide the comprehensive and reliable
conclusion, we performed the present meta-analysis of 8
independent case-control studies [18-24], including
11356 patients and 11641 controls. According to the
study design, 3 studies were conducted in a population-
based design [20,22,24], and 5 in a hospital-based design
[18,19,21,23]. Some studies reported insufficient infor-
mation about recruitment methodology and study parti-
cipant characteristics, particularly for controls. The
control populations were not uniform. Healthy popula-
tions as well as non-cancer patients were included.
Some individuals in the control group are likely to
develop cancer in subsequent years though they had no
clinical symptoms at the time of investigation. Our
results indicated that the rs2745557 was associated with
Figure 1 Cox-2 rs2745557 was associated with a lower PCa risk under dominant model in overall population (TT + TC versus CC). The
squares and horizontal lines correspond to the study specific OR and 95% CI. The area of the squares reflects the weight (inverse of the
variance). The diamond represents the summary OR and 95% CI.
Figure 2 Cox-2 rs2745557 was associated with a lower PCa risk under dominant model in Caucasians (TT + TC versus CC). The squares
and horizontal lines correspond to the study specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The
diamond represents the summary OR and 95% CI.
Zhang et al. BMC Immunology 2012, 13:14
http://www.biomedcentral.com/1471-2172/13/14
Page 4 of 7al o w e rP C ar i s ku n d e rd o m i n a n tm o d e li no v e r a l l
population. Nevertheless, considering that rs2745557
polymorphism may play different roles in PCa suscept-
ibility among different ethnic subgroups and the fre-
quencies of rs2745557 polymorphism might be different
among different ethnic groups which might contribute
to the possible presence of heterogeneity between the
studies, we further conducted subgroup analysis by eth-
nicity in current meta-analysis. In the stratified analysis
by ethnicity, our results suggested that COX-2
rs2745557 polymorphism was associated with a lower
PCa risk among subjects of Caucasians. We found that
COX-2 rs2745557 polymorphism was associated with a
trend of decreased PCa risk under dominant model and
allelic model in African Americans, however significant
relation was absent in Asians. There may be many fac-
tors influencing the result, such as differences in popula-
tions, selection factors and so on. The rs2745557 was
associated with a lower PCa risk under dominant model.
However, the significant association is completely lost
under homogeneous co-dominant model or allelic
model. So we can speculate that rs2745557 may associ-
ate with a lower PCa risk under over-dominant model.
However, the significant association was absent. The
reason for this phenomenon may be caused by a lack of
sufficient genotype data in several studies. Considering
the limited studies and population numbers of African
Americans and Asians included in the meta-analysis,
this may increase the risk of false negative findings, any
conclusions at overall population level should be inter-
preted with caution. Therefore, we are not sure whether
there is a significant association between the COX-2
polymorphism and decreased PCa risk in the whole
population due to low statistical power.
Heterogeneity is a potential problem when interpret-
ing the results of the present meta-analysis. In overall
analysis, significant between-study heterogeneity existed
in dominant model, heterogeneous co-dominant model,
over-dominant model and allelic model comparisons.
After subgroup analyses by ethnicity, the heterogeneity
was removed under allelic model in Caucasians. In this
meta-analysis, high levels of heterogeneity were observed
in some comparisons. There are some factors that could
have contributed toward the high heterogeneity. First,
t h e r ei sl i k e l yt ob ec o n s i d e r a b l eg e n e t i ch e t e r o g e n e i t y
between the samples that were drawn from geographi-
cally diverse populations. It is known that genotype dis-
tributions differ across populations, and genotype-
phenotype associations may also depend on population
stratification. Second, definition of control group is dif-
ferent in different studies, the definition differences of
the controls could have contributed to the high hetero-
geneity observed in our meta-analysis. Third, we
attempted to determine if the high heterogeneity might
also be explained by other variables such as stages of
PCa, smoking status, and environmental factors included
in the different studies, but are unable to provide a reli-
able answer to this question because we did not have
access to individual level data for these variables.
Some limitations of this meta-analysis should be
acknowledged. First, because only published and English
articles were included in the meta-analysis, publication
and potential English language biases may have
occurred, even though it was not found by making use
Table 2 Meta-Analysis of COX-2 rs2745557 Polymorphisms and Prostate Cancer
Genetic model
(No. of studies)
Sample size Analysis model Test of association P value for Egger’s test Test for heterogeneity
Case Control OR (95% CI) P P I
2
Total (8)
TT vs CC (5) 7371 7412 F 1.04 (0.88-1.23) 0.66 0.510 0.74 0%
TC vs CC (5) 9737 9959 R 0.88 (0.74-1.04) 0.14 0.275 0.05 58%
TT vs TC + CC (5) 10020 10234 F 1.06 (0.89-1.25) 0.51 0.627 0.81 0%
TT + TC vs CC (8) 11356 11641 R 0.85 (0.74-0.97) 0.02 0.062 0.01 60%
TC vs TT + CC (5) 10020 10234 R 0.88 (0.75-1.04) 0.13 0.276 0.06 56%
T vs C (5) 20040 20468 R 0.92 (0.80-1.06) 0.26 0.284 0.07 55%
Caucasian (6)
TT vs CC (3) 7132 7024 F 1.05 (0.89-1.25) 0.56 0.77 0%
TC vs CC (3) 9435 9446 R 0.91 (0.76-1.10) 0.33 0.04 68%
TT vs TC + CC (3) 9713 9709 F 1.07 (0.90-1.27) 0.43 0.80 0%
TT+TC vs CC (6) 11049 11116 R 0.86 (0.75-0.99) 0.04 0.02 64%
TC vs TT + CC (3) 9713 9709 R 0.91 (0.76-1.09) 0.31 0.04 68%
T vs C (3) 19426 19418 F 0.97 (0.92-1.03) 0.32 0.11 55%
OR odds ratio, CI confidence interval, vs versus, R, random effect model, F, fixed effect model
Zhang et al. BMC Immunology 2012, 13:14
http://www.biomedcentral.com/1471-2172/13/14
Page 5 of 7of statistical test. Second, the result should be cautiously
interpreted because controls were not uniformly defined.
Non-differential misclassification bias was possible
because these studies may have included controls that
had different risks for developing PCa. Third, only one
study analyzed Asian population and another one Afri-
can American population in this study. So it is quite
important to have more studies and sample of Asians,
Africans, and African Americans in the future so that
more precise conclusion about the associations between
rs2745557 polymorphism and PCa risk could be
achieved. Fourth, our results were based on unadjusted
estimates, while a more precise analysis should be con-
ducted adjusted by other factors like smoking, drinking
status and environmental factors. In addition, our analy-
sis did not consider the possibility of gene-gene or SNP-
SNP interactions or the possibility of linkage disequili-
brium between polymorphisms. Further investigations of
the haplotypic effect of a gene and the study of multiple
polymorphisms in different genes are needed.
Conclusions
In conclusion, our meta-analysis suggested that there
was an association between rs2745557 polymorphism
and lower PCa risk in Caucasians. Due to limitations
showed above in this analysis, it is critical that larger
and well-designed multicenter studies are needed to
confirm our results.
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